Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.5 which represents a decrease of $-1.03 or -0.57% from the prior close of $179.53. The stock opened at $179.2 and touched a low of $176.18 ...

The merger combines two of the country's largest power generators as demand for electricity surges. Airline stocks have been doing well recently, and the results suggest that can continue. The ...

Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for AbbVie in a research note issued to investors ...

The stock market saw something incredible in 2024, with the “Magnificent 7” tech giants leading the charge and driving a huge ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 6. Analyst David Risinger ...

Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $179.53 which represents a decrease of $-0.57 or -0.32% from the prior close of $180.1. The stock opened at $179.63 and touched a low of ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on AbbVie (ABBV – Research Report) yesterday and set a price target of ...